Humana Announces Pricing for Senior Note Tender Offers

Humana (HUM) announced pricing for tender offers on eight senior note series, with a total cap of $1.5B. The offers, expiring Nov 16, 2026, include an $800M cap on 5.375% notes due 2031. Consideration ranges from $852.68 to $1,005.77 per $1,000 principal. Analysts have a Buy rating with a $563 target, but TipRanks' AI rates it Neutral.

Original reporting
Published Nov 17, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$HUM
Neutral
medium confidence
Mentioned
$HUM
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$HUMNeutralMed
01

Why it matters

The disclosed consideration range, purchase caps, and expiration deadline are the key tradable details, as they affect expected debt reduction and near-term credit risk perception.

02

Market read

Traders may adjust HUM credit and equity expectations around balance-sheet risk as the tender deadline approaches and results are finalized.

03

What to watch

Final acceptance levels and proration across note series can materially affect the net debt reduction and interest savings, which the article does not quantify.

Relevance 7/10Novelty 6/10Timing: tender offers expire at 5 p.m. New York time on Nov. 16, 2026

Background

Humana is conducting cash tender offers to repurchase multiple outstanding senior note series, a common strategy to manage maturity walls and coupon burden.

Company-level read

Ticker impact

$HUMNeutralMedium confidence
Context

Humana priced cash tender offers for eight series of senior notes, including an $800 million cap on its 5.375% 2031 notes, expiring 5 p.m. ET.

Expected impact

Likely modest support as markets interpret the tender as disciplined balance-sheet management, tempered by uncertainty around final acceptance/proration and funding costs.

Evidence & confidence

The article provides concrete tender terms (consideration range, caps, expiration time) but does not include a new equity catalyst or guidance change beyond what is described as analyst commentary.

Market effects

Shows continued use of debt tendering by managed-care issuers, which can influence sector credit spreads and refinancing expectations.

Limited direct impact beyond US credit markets for healthcare issuers.

Low, as the event is issuer-specific and tied to US senior notes.

Counterpoint

Tender pricing could reflect less favorable market conditions for Humana’s debt, so the market may read it as a sign of tighter credit rather than purely proactive management.

Key entities

  • Humana Inc.

    Subject of the tender offer pricing update for eight series of outstanding senior notes.

Related articles

$HUMMed

Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

HUMANA INC (HUM) filed an SEC Form 8-K — Other Events. news release Humana Inc. 101 East Main Street Louisville, KY 40202 Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities Louisville, KY - November 16, 2026 - Humana Inc. (NYSE: HUM) (“ Humana ”, “ we ”, or “ our ”) today announce

$HUMMed

Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

Humana Inc. (HUM) announced pricing terms for its cash tender offers to purchase certain outstanding debt securities, totaling up to $1.5 billion. The offers include various senior notes due between 2027 and 2032, with specific acceptance priorities and caps. The total consideration per $1,000 principal amount varies by note series, ranging from $852.68 to $1,005.77. The offers expire on November 16, 2026, with a settlement date expected on November 18, 2026.

$HUMHigh

Why is Humana stock climbing today?

Humana Inc (HUM) stock rose 2.2% in pre-market trading after RBC Capital upgraded it to 'Outperform' and raised its price target to $563. The move follows Humana's Q3 2026 earnings beat, with revenue of $41.16 billion and raised full-year EPS guidance to at least $9.50. Multiple analysts have upgraded the stock, citing improving Medicare Advantage ratings and cost outlook.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.